| 得力生注射液联合肝动脉栓塞化疗和门静脉化疗对肝癌治疗的价值 |
| |
| 引用本文： | 林青,陈汝福,李志花,郭宁,周泉波. 得力生注射液联合肝动脉栓塞化疗和门静脉化疗对肝癌治疗的价值[J]. 中华普通外科学文献(电子版), 2008, 2(5): 30-31 |
| |
| 作者姓名： | 林青 陈汝福 李志花 郭宁 周泉波 |
| |
| 作者单位： | 1. 中山大学孙逸仙纪念医院肝胆外科,广州,510120
2. 中山大学孙逸仙纪念医院肿瘤科,广州,510120 |
| |
| 摘 要： | 目的探讨得力生注射液经肝动脉、门静脉途径应用，对预防肝癌术后复发转移的治疗作用。方法选择原发性肝癌切除术后行肝动脉、门静脉化疗的患者60例。将患者随机分成两组，联合得力生注射液经肝动脉和门静脉治疗组30例，对照组30例。检测和分析化疗前、后不同时期体液免疫指标、生活质量改善和复发率。结果两组患者随访3～24个月，对照组肿瘤肝内复发15例次，治疗组肿瘤肝内复发13例次，两组间无统计学差异；治疗组的体液免疫指标IgG、IgA、IgM浓度和生活质量评分有显著提高（P〈0．05），且化疗的毒副作用明显减少。结论得力生注射液联合肝动脉栓塞化疗和门静脉化疗治疗肝癌术后患者，可提高免疫力，改善生活质量；通过肝动脉和门静脉途径给药，可增强疗效，并能减少化疗的副作用。
|
| 关 键 词： | 肝肿瘤/治疗 肝切除术 化疗栓塞 治疗性 得力生 复发 |
Value of delisheng combined with hepatic artery chemoembolization and portal vein chemotherapy in hepatocellular carcinoma |
| |
| LIN Qing,CHEN Ru-fu,LI Zhi-hua,GUO Ning,ZHOU Quan-bo. Value of delisheng combined with hepatic artery chemoembolization and portal vein chemotherapy in hepatocellular carcinoma[J]. Chinese Journal of General Surgery(Electronic Version), 2008, 2(5): 30-31 |
| |
| Authors: | LIN Qing CHEN Ru-fu LI Zhi-hua GUO Ning ZHOU Quan-bo |
| |
| Affiliation: | LIN Qing,CHEN Ru-fu,LI Zhi-hua,GUO Ning,ZHOU Quan-bo Department of general surgery,the second affiliacted hospital of Sun Yat-sen University,Guanzhou 510120,China |
| |
| Abstract: | Objective To study the value of delisheng combined with hepatic artery chemoembolization(HACE) and portal vein chemotherapy(PVC) after radical resection in hepatocellular carcinoma(HCC) for preventing recurrence. Methods 60 cases of HCC were treated with HACE and PVC after radical resection. 30 cases of them accepted delisheng treatment for one week at the same time ,the other 30 cases were used as controls. Effect of delisheng combined with HACE and PVC on postoperative recurrent rate was evaluated. Change... |
| |
| Keywords: | Liver neoplasms/therapy Hepatectomy Chemoembolization therapeutic Delisheng Recurrence |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
